资讯

Clinical Trials Arena on MSN10 天
Vaxcyte stock sinks despite Phase II IPD vaccine trial success
Vaxcyte is awaiting data from another vaccine candidate for invasive pneumococcal disease (IPD) before advancing to Phase III ...